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Background: A subset of breast cancer cells displays increased ability to self-renew and reproduce breast cancer
heterogeneity. The characterization of these so-called putative breast tumor-initiating cells (BT-ICs) may open the road
for novel therapeutic strategies. As microRNAs (miRNAs) control developmental programs in stem cells, BT-ICs may also
rely on specific miRNA profiles for their sustained activity. To explore the notion that miRNAs may have a role in
sustaining BT-ICs, we performed a comprehensive profiling of miRNA expression in a model of putative BT-ICs enriched
by non-attachment growth conditions.
Results: We found breast cancer cells grown under non-attachment conditions display a unique pattern of miRNA
expression, highlighted by a marked low expression of miR-30 family members relative to parental cells. We further
show that miR-30a regulates non-attachment growth. A target screening revealed that miR-30 family redundantly
modulates the expression of apoptosis and proliferation-related genes. At least one of these targets, the anti-apoptotic
protein AVEN, was able to partially revert the effect of miR-30a overexpression. Finally, overexpression of miR-30a
in vivo was associated with reduced breast tumor progression.
Conclusions: miR30-family regulates the growth of breast cancer cells in non-attachment conditions. This is the first
analysis of target prediction in a whole family of microRNAs potentially involved in survival of putative BT-ICs.
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Breast tumor initiating cells (BT-ICs) are functionally de-
fined by their unlimited renewal potential and ability to re-
produce tumor heterogeneity, attracting attention as
therapeutic targets [1,2]. There is growing evidence that
molecular pathways required for normal stem cell func-
tions are deregulated in BT-ICs [3]. As occurs with normal
organogenesis and cell differentiation, the selective activa-
tion and repression of these pathways may be mediated by
microRNAs (miRNAs). These short non-coding RNAs in-
hibit gene expression by mRNA degradation or transla-
tional inhibition [4,5]. Their importance in establishing
developmental programs of expression is illustrated by the
requirement of miRNA processing proteins like Dicer* Correspondence: vargash@iarc.fr
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distribution, and reproduction in any mediumduring embryogenesis [6], and the presence of specific
miRNAs in pluripotent cells [7]. Since miRNAs drive ter-
minal differentiation, downregulation of specific miRNAs
may play an important role in the development and pro-
gression of cancer [8], including breast cancer [9]. There-
fore, the aberrant expression of specific miRNAs could
lead to a pathologic expansion of immature cells. To gain
insight into this untested hypothesis, we performed a
miRNA profiling in putative BT-ICs enriched from breast
cancer cell lines. Our studies revealed a family of miRNAs
that play a key role in defining features of these cells. We
further identified and validated the targets of this family of
miRNAs and studied its role in survival of BT-ICs in vitro
and in vivo.
Results
MicroRNA profiling in putative BT-ICs
Because of their role in defining expression programs in
development and cancer, we investigated whether miRNA
expression displayed a particular profile in putative BT-ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 miRNA profiling in mammospheres. An oligonucleotide array was used for comparing the miRNA expression between
mammospheres (MMO) and parental MCF7 cells. A. Scatter plot of 2 technical replicates showing a significant correlation for all miRNA probes.
B. Unsupervised clustering distinguishing MMO from parental MCF7 cells and from MMO plated in attachment conditions (DIFF MMO). C. Scatter
plot comparing MMO and MCF7 parental cells. Upregulated and downregulated miRNAs are shown in red. Green dots represent miRNAs
significantly downregulated in MMO after class comparison analysis (no miRNA was significantly upregulated in MMO). D. Cluster and heat-map
analyses are shown for the MMO/MCF7 comparison. miRNAs significantly downregulated in MMO match the miRNAs represented in green in
Figure 1C. E. Two miRNAs from the previous analysis (miR-30a and miR-26a) were validated using TaqMan probes in independent samples. F.
miR-30a expression was studied in an unrelated breast cancer cell line, 4T1. Mammospheres derived from 4T1 cells expressed significantly lower
levels of miR-30a. P value under 0.05 (two-tailed student t test) is represented with an asterisk (*).
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which stem-like cells are capable of forming suspended
spheres, has been extensively used to enrich cultures for
BT-ICs [10]. We used the mammosphere system to com-
pare MCF7 BT-ICs with their parental cell line in a miRNA
oligonucleotide array covering 474 human miRNAs. In
addition, we plated MCF7-derived mammospheres back to
attachment conditions to induce their reconfiguration into
an epithelial monolayer (here referred to as “differentiated
mammospheres”). Independent biological replicates dis-
played high consistency (Figure 1A), while unsupervised
clustering discriminated mammospheres from parental
MCF7 cells (Figure 1B and Additional file 1: Figure S1A).
In contrast, parental MCF7 cells and “differentiated”
mammospheres displayed a similar miRNA profile and
clustered together after unsupervised analyses, suggesting
that mammospheres retained the ability to revert their
miRNA expression profile to the original conditions
(Figure 1B, and Additional file 1: Figure S1B). Class com-
parison analyses showed that 8 human miRNAs were dif-
ferentially expressed between mammospheres and parental
MCF7 cells (p value <0.001, FDR<0.1), including miR-345,
miR-367, miR-26a, and five members of the miR-30 family
(Figure 1C, 1D, and Table 1). All these miRNAs were strik-
ingly downregulated in mammospheres (between 8-fold
and 22-fold), while their expression increased close to
basal levels after plating the mammospheres back to attach-
ment conditions (Additional file 2). When performing a
class comparison analysis among the 3 groups (MCF7,
mammospheres, and “differentiated” mammospheres),
miR-30a-5p displayed the most consistent capacity to
distinguish mammospheres from the other two groups
(lowest p and FDR values).
No miRNAs were significantly overexpressed in mam-
mospheres, and therefore we focused our attention in those
miRNAs significantly downregulated. Results were vali-
dated using an independent expression array platform, to-
gether with specific Taqman qRT-PCR assays. Results
obtained with the Illumina Human v2 bead array, wereTable 1 miRNAs differentially expressed in
mammospheres
Symbol MCF7 MMO Fold-change
hsa-mir-30c 670.5 59.69 11.23
hsa-mir-30b 566.7 44.93 12.61
hsa-mir-30c-1 289.3 13.11 22.07
hsa-mir-367 45.6 2.13 21.37
hsa-mir-30a-5p 355.7 43.7 8.14
hsa-mir-30d 1393 142.04 9.81
hsa-mir-26a-2 201.2 17.16 11.73
hsa-mir-345 178.1 22.34 7.97
Mean expression values and fold-change (MCF7/MMO) are shown for MCF7
cells and MCF7-derived mammospheres (MMO). P-value < 0.001, FDR < 0.1.consistent with the oligonucleotide array data, showing no
significantly overexpressed miRNAs in mammospheres
(Additional file 3: Figure S2A-C). miR-30a was the most
significantly down regulated miRNA in mammospheres
compared to parental MCF7 cells, while miR-26a and miR-
345 were also found to be significantly downregulated
(Additional file 3: Figure S2D). The differential expression
of several miRNAs including miR-30a and miR-26a were
further confirmed using TaqMan probes (Figure 1E). Abso-
lute copy number quantification was performed by using a
standard miR30a probe at different dilutions (Additional
file 4: Figure S3A and Figure S3B). Extrapolating to these
standards, we defined an average of approximately 20
copies of miR-30a per MCF7 cell. This is significantly
higher than the 1 copy per cell obtained in mammospheres
(Additional file 3: Figure S2B). In addition, a significant
down-regulation of miR-30a expression was found in mam-
mospheres derived from the non-related mammary cancer
cell line, 4T1, relative to parental 4T1 cells (Figure 1F).
These results have revealed a panel of differentially
expressed miRNAs, and demonstrated that miR-30 family
downregulation is not cell line specific, and may indeed play
an important role in mammosphere formation and main-
tenance of cell growth under non-attachment conditions.miR-30a regulates non-attachment growth in putative BT-
ICs
Among differentially expressed miRNAs in mam-
mospheres, miR30a-5p (referred to here and thereafter as
miR30a) displayed the most consistent (across all plat-
forms) and significant downregulation (lowest p value).
Therefore, we chose to address the functional role of this
miRNA in putative BT-ICs. We experimentally modulated
miR-30a levels and studied the capacity to form
mammospheres in vitro, as an extensively used assay to
estimate the capacity of self-renewal and proliferation
[10-12]. To this end, MCF7 breast cancer cells were
transfected with either miR-30a inhibitor (KD) oligos (to
suppress its expression), or pre-miR-30a precursor oligos
(to overexpress miR-30a) during 48 hours, and studied
cellular response to downregulation and overexpression of
miR30a. As a control, cells were also transfected with
miR-159 inhibitor (KD) oligos, a miRNA known to lack
targets in the human genome [13] (Figure 2A and
Additional file 4: Figure S3C). We found a dramatic reduc-
tion in the number of mammospheres formed after over-
expression of miR-30a in MCF7 cells (mean 2.66 spheres/
well compared to more than 50 spheres/well in control
miR-159-KD, p<0.01) (Figure 2B). In contrast, miR-30a
KD transfection significantly enhanced the formation of
mammospheres in MCF7 cells (Figure 2B). Inhibition or
overexpression of miR-30a did not affect mammospheres
morphology or size (Figure 2C).
Figure 2 Sphere formation assay after modulation of miR-30a expression. MCF7 and 4T1 breast cancer cells were transiently transfected
with miR-30a knock-down (KD), Pre-miR-30a, and miR-159 KD control probes. Efficiency of transfection was verified by TaqMan qRT-PCR (A, D).
48 hours following transfection, cells were used in a mammosphere assay (B, E). MMO were counted after 4 days. Technical triplicates were used
for statistical analyses, with one representative experiment shown (C, F). P values (for comparisons to control miR-159 KD) under 0.05 (two-tailed
student t test) are represented with an asterisk (*).
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regulation in mammosphere formation, we transfected an
independent breast cancer cell line (4T1) with miR-30a KD
and pre-miR-30a precursor oligos and examined its ability
to grow in non-attachment conditions. In general, 4T1 cells
displayed an enhanced ability to produced mammospheres
compared to MCF7 cells, consistent with the higher inva-
siveness and metastatic potential of these cells. Importantly,
also in 4T1 cells, transfection with pre-miR-30a resulted
in a striking reduction in 4T1-derived mammosphere
formation (mean 152 spheres/well compared to almost 400
spheres/well in control miR-159-KD, p<0.01) (Figure 2D-
2F), consistent with the results obtained in MCF7 cells.
However, in contrast to MCF7 cells, we observed a slight
(although statistically significant) reduction in the number
of mammospheres after downregulation of miR-30a (mean
341, p=0.03) (Figure 2E). Of note, transfections did not have
any effect in cell growth and viability of parental 4T1 and
MCF7 cells. Together, these results revealed a functional
role of miR-30a in sustaining the growth of breast cancer
cells in non-attachment conditions and suggest that miR-30a may regulate essential pathways for the self-renewal of
putative BT-ICs.Identification of miR-30a target genes in putative BT-ICs
miRNAs are able to regulate their target genes by decreas-
ing their mRNA levels [14]. Therefore, we screened for
miR-30a targets using whole genome expression bead ar-
rays after transfecting MCF7 cells with miR-30a-KD probe
and miR-30a precursor, as well as miR-159-KD (control)
oligos (Figure 3A). This assay produced high quality data
with strong correlation between biological replicates
(Additional file 5: Figure S4A). Although unsupervised
clustering was able to clearly distinguish MCF7 cells over-
expressing miR-30a, samples from cells inhibited for miR-
30a clustered together with control samples (Additional file
5: Figure S4B). Consistent with this finding, although 227
genes were differentially expressed between pre-miR-30a-
transfected and control cells, our analysis showed no dif-
ferentially expressed genes between the miR-30 KD and
control cells (Figure 3A). As miR-30 KD oligos had a
Figure 3 Whole genome expression after modulation of miR-30a expression. Same transfections described in Figure 2 were done before
transcriptome analyses. A. Strategy for identification of potential miR-30a targets. As shown, no significant differences were found between miR-30a-KD
and control miR-159-KD cells. Therefore, downstream analyses focused on the Pre-miR-30a conditions. B. Scatter plot comparing Pre-miR-30a to miR-
159-KD control condition. From 227 significant genes in this comparison, 86 were downregulated, 36 of which contained a miR-30a seed sequence. C.
Validation of a subset of these 36 genes was done with qRT-PCR (see also Additional file 4: Figure S3). Gene expression values are relative to HPRT1
housekeeping gene. P values (for comparisons to control miR-159 KD) under 0.05 are represented with an asterisk (*). D. Target validation was done
after cloning 30UTR sequences of AVEN and FOXD1 into a luciferase reporter plasmid and transfection of MCF7 cells. P value under 0.05 (two-tailed
student t test) is represented with a (*).
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Table 2 Putative targets of miR-30a after whole genome
expression (WGE) analysis of miR-30a overexpression
Gene name Pre-miR-30a miR-159 k.d. Fold-change Score
ACP2 103.98 160.67 0.65 −6.23
ARID5B 97.55 145.53 0.67 −2.96
ARVCF 44.57 61.42 0.73 −2.66
ATG12 134.92 192.78 0.70 −3.36
AVEN 89.8 166.93 0.54 −9.51
BNIP3L 64.7 95.14 0.68 −4.93
C14orf129 165.21 278.97 0.59 −1.92
C1orf19 291.73 475.23 0.61 −11.7
C2orf30 175.86 317.2 0.55 −10.18
C3orf57 855.03 1500.97 0.57 −1.39
CHMP2B 294.63 447.1 0.66 −7.54
DCUN1D3 85.59 141.19 0.61 1.38
DPY19L1 194.24 277.5 0.70 −4.87
DPYSL2 315.4 502.3 0.63 −5.31
EDG3 100.43 149.23 0.67 −1.99
ELMOD2 81.24 123.28 0.66 1.74
FAM18B 121.66 169.09 0.72 −4.05
FOXD1 104.98 150.49 0.70 −2.49
GNAI2 229.93 496.33 0.46 −11.2
GNG10 91.32 139 0.66 −7.76
GNPDA1 489.02 831.37 0.59 −0.6
KDELC2 116.08 204.6 0.57 −3.39
KIAA0241 99.59 151.45 0.66 −2.69
NECAP1 157.52 253.56 0.62 −6.58
PDSS1 257.51 381.04 0.68 5.63
PGM1 196.55 309.58 0.63 −6.5
PIK3R2 762.04 1060.6 0.72 −5.76
PPP1R2 279.79 504.81 0.55 −9.54
REEP3 56.69 79.57 0.71 −5.93
REXO4 174.68 257.94 0.68 −6.87
RPA2 385.11 641.74 0.60 −1.52
SEC23A 54.91 75.17 0.73 −4.48
TFDP1 709.63 1059.53 0.67 −7.84
TM4SF1 436.61 828.33 0.53 −6.84
TRIB3 277.11 422.9 0.66 −2.06
VKORC1L1 335.84 525.07 0.64 −3.44
Significantly downregulated genes after Pre-miR-30a transfection. Only
potential targets with 30UTR seed sequences of miR-30a are included. “Scores”
are based on the PITA algorithm, as described in Materials and Methods.
Targets common to miR-30 family WGE analysis are underlined.
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sult indicates that biologically significant targets may fall
below the sensitivity of the assay or the thresholds used for
the analyses (as discussed below). Among 227 differentially
expressed genes in pre-miR-30a transfected cells, there
were 86 genes downregulated, suggesting that these may
be direct targets of miR-30a (Figure 3B). The miRNA seed
sequence serves to direct the miRNA to its mRNA targets
[15]. Therefore, to identify the genes that are likely to be
bona fide targets of miR-30a, we took advantage of publicly
available algorithms to identify the genes with 30UTR re-
gion containing miR-30a seed sequences (Table 2 and
Additional file 2). Our analysis identified 36 potential tar-
gets, some of which (such as SEC23A) have been previ-
ously reported [5]. For validation, we chose a subset of
differentially expressed genes (including the apoptosis-
related gene AVEN, the transcription factor-related genes
FOXD1 and TFDP1, and previously validated targets such
as IDH1 and SEC23A). In all cases, qRT-PCR confirmed
the bead array results using independent biological repli-
cates (Figure 3C and S4C). Importantly, this validation
confirmed the downregulation of potential miR-30a targets
after miR-30a overexpression, whereas no difference in
gene expression between miR-30a-KD and miR-159-KD
control transfected cells was found (Figure 3C and
Additional file 5: Figure S4C), consistent with the bead
array transcriptome data.
Among the significantly downregulated genes, we
selected FOXD1 and AVEN for further validation using
luciferase assays. AVEN was amongst the most signifi-
cantly downregulated genes after miR-30a over-expres-
sion, while FOXD1 was a predicted miR-30a target by 6
different algorithms (miRanda, PicTar, PITA, TargetScan,
RNAhybrid, and MiRTarget2). We cloned the 30UTR se-
quences of FOXD1 and AVEN, containing the seed se-
quence of miR-30a, in pGL3 control vector expressing
constitutively the luciferase gene. A construct containing
the 30UTR sequence lacking the complete miR-30a seed
sequence was used as a control. These constructs were
transfected into MCF7 cells, which express low, but de-
tectable, levels of endogenous miR-30a (Figure 2 and
Additional file 4: Figure S3). A significant reduction in
luciferase expression was observed after transfection
with both 30UTR constructs, compared to pGL3 control
(Figure 3D). Moreover, a further reduction in luciferase
activity was observed after overexpressing miR-30a in
co-transfected cells (Figure 3D). These results suggest
that miR-30a is specifically targeting the 30UTR regions
of FOXD1 and AVEN. Together, these findings support
the differentially expressed genes as direct targets of miR-
30a and thus they may play a major role in mammosphere
growth. However, a potential compensatory effect by other
members of the miR-30 family may explain the lack of ef-
fect after efficient downregulation of miR-30a.miR-30 family displays gene target redundancy in breast
cancer cells
Although the large majority of miRNA targets remain
unknown, there is evidence for redundant target specifi-
city of unrelated miRNAs, or miRNAs from the same
family [16,17]. Our data on miR-30a knocked-down cells
suggested a compensatory effect by other member of the
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within the miR-30 family, we used a custom-designed
probe-set to simultaneously inhibit all 5 members of the
family: miR-30a, b, c, d and e. A significant downregulation
of all miR30 microRNAs was observed after transfection
with family inhibitor probe-set, confirming the global effect
of the family inhibitor (Figure 4A). Moreover, downregula-
tion of the miR-30 family correlated with overexpression of
one of the new potential target genes, AVEN, an effect not
observed when only miR-30a was inhibited (Figure 4B).
Next, we performed a new transcriptome analysis on
MCF7 cells transfected with miR-30 family KD probes,
miR-30 precursor or miR-159 KD (control). In contrast to
the first whole genome expression analysis, a three class
comparison revealed this time 330 differentially expressedFigure 4 Whole genome expression after modulation of miR-30 famil
oligonucleotides, as described in Methods. A. Efficiency of KD in MCF7 cell
family. B. a potential new target of miR-30a, AVEN, was also checked. C. Str
Figure 3A, class comparison analysis was able to show 330 miRNAs differen
upregulated after miR-30 family KD and downregulated after miR-30a over
sequence. P value under 0.05 (two-tailed student t test) is represented withgenes distinguishing the three classes (p<0.001, FDR<0.15).
We next looked for those genes simultaneously upregulated
after KD and downregulated after precursor transfection, as
they were most likely to be direct targets (Figure 4C). We
found 236 genes that overlapped between these two condi-
tions. Out of these, 118 genes were found to have a 30UTR
region containing miR-30a seeds. Importantly, this analysis
revealed that among the genes whose expression is most
strongly influenced by miR-30 family KD were IDH1,
AVEN and FOXD1, all of which had been identified in the
previous transcriptome analysis (Table 2). Indeed, out of 36
targets of miR30a identified in the first screening, 26 (72%)
were also identified after silencing miR30 family in the
second screening. Moreover, this last screening included 8
experimentally validated targets of miR-30 [5], such asy expression. miR30 family knock-down was obtained by using 2
s was checked by TaqMan qRT-PCR for five members of the miR-30
ategy for identification of potential miR-30a targets. As opposed to
tially expressed between the 3 classes. 236 genes were commonly
expression. Out of these, 118 genes contained a miR-30a seed
a (*).
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ous whole genome expression analysis. These results
suggest that miR-30 family members display target redun-
dancy, and the downregulation of all of its members is ne-
cessary for growth under non-attachment conditions.
To define functional enrichment of miR30 targets, we
used the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID ) v6.7. First, we used the final
list of 118 putative targets of miR30 family of miRNAs.
However, no significant enrichment was found for any
functional category or pathway when using the whole hu-
man transcriptome as a reference. Next, we performed en-
richment analyses in the extended 330 genes list, that
represents all transcripts significantly regulated (in any
direction) after miR30 family modulation, independently
of the presence of a putative seed sequences in their
30UTR. We analyzed their enrichment in specific Gene
Ontology (GO) categories, and biological pathways
(BioCarta and KEGG). Only those categories with p value
< 0.005 for three different statistical tests (LS and KS per-
mutation, and Efron-Tibshirani’s GSA test), were consid-
ered as statistically significant. Top significant GO category
was cytokinesis, while both GO and BioCarta pathway ana-
lyses were significant for a number of metabolic processes
(e.g. cellular aldehyde, acetyl-CoA, reductive carboxylate
cycle, and galactose metabolism) (Additional file 6). Inter-
estingly, KEGG pathway analysis produced two significant
categories: Polyadenylation of mRNA, and EGF Signaling
Pathway. Polyadenylation is known to be involved in
mRNA stability, while EGF signalling has been shown to
promote cancer cell proliferation and to enhance mam-
mosphere formation [18].
miR-30 overexpression impairs breast cancer tumor
formation
To explore the in vivo role of miR-30a, we induced tumors
by injecting 4T1 cells in the mammary fat pads of im-
munocompetent BALB/c mice. We chose 4T1 cells be-
cause its patterns of tumor growth at the primary site of
injection and the metastatic spread in BALB/c mice
closely mimic human breast cancer [19]. Prior to s.c. injec-
tion, 4T1 cells were transiently transfected with miR-30a
-KD, pre-miR-30a or control miR-159-KD oligos. After
3 weeks, tumors induced with miR-30a overexpressing
4T1 cells (pre-miR-30) were significantly smaller and
lighter than control and miR-30a KD tumors (Figure 5A
and 5B). Tumours collected after 3 weeks were dissociated
and plated under mammosphere conditions to quantify
their sphere formation potential. Interestingly, cells de-
rived from both, miR-30a-KD and pre-miR-30a, displayed
a lower ability to form spheroids in vitro. Although this
difference was not significant for miR-30a-KD, it was bor-
derline significant for pre-miR-30a (p=0.07) (Figure 5A,
lower panel). To further explore the potential role of othermembers of miR-30 family, this experiment was replicated
using simultaneous inhibition of the miR-30 family (miR-
30 family KD), as described above. Similar to the previous
experiment, only miR-30a overexpression was able to in-
duce significantly smaller tumors under these conditions
(Figure 5B). No significant differences were observed after
miR-30 family KD. In addition, a trend for a reduced
number of ex-vivo spheroids was again observed with pre-
miR-30a (Figure 5B, right panel). Importantly, several
studies have suggested a metastatic behavior for putative
BT-ICs. Therefore, we next studied the induction of lung
metastasis under modulation of miR-30. A non-significant
reduction in the number of metastatic colonies was ob-
served after miR-30a overexpression (Additional file 7:
Figure S5A and Figure S5B). Interestingly, while the num-
ber of mammospheres did not correlate significantly with
tumor weight or volume, it significantly correlated with
the number of colonies (r=0.37, pval=0.042). Therefore, a
higher ability to produce spheres ex vivo correlated with a
higher number of lung colonies in the clonogenic assay.
This suggests a link between the ability to grow in non-
attachment conditions and the metastatic behavior in vivo.
Together, these in vivo experiments support an important
role for miR-30 in regulating the mammary cancer cells
responsible for tumor growth.
AVEN overexpression can rescue mammosphere growth
in presence of miR30a
The biological role of miRNAs is the result of simultan-
eously targeting multiple transcripts [20]. In this sense,
we expect that miR30 role in non-attachment growth is
probably the result of multiple target regulation. How-
ever, we were interested in investigating in more detail
the role of AVEN, because of the link between increased
expression of this protein and cell survival [21], and
poor prognosis in different types of human malignancies
[22,23]. Moreover, the role of AVEN has been specific-
ally addressed in breast cancer cells, including MCF7
cells [24]. We used endoribonuclease-prepared siRNA
pools (esiRNA) targeting AVEN coding sequence to tran-
siently silence AVEN expression in MCF7 cells. Two
days after siRNA we tested the effect of AVEN silencing
on a sphere formation assay, as described above. Import-
antly, we found that silencing significantly impaired
sphere formation when compared to a non-targeting
control siRNA (P<0.05) (Figure 6A). In addition, we used
plasmid overexpression to further understand the role of
AVEN in sphere formation. To this end, we used an ex-
pression plasmid encoding for full length AVEN. We se-
lected a plasmid concentration that increased AVEN
expression without affecting cell survival. Western blots
performed 48 hours after transfection of MCF7 cells
showed a higher AVEN expression relative to cells
transfected with empty-vector (Figure 6B). Under non-
Figure 5 (See legend on next page.)
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Figure 5 Role of miR-30 in tumor progression and metastasis. A. 4T1 mammary cancer cells were transiently transfected with miR-30a KD,
Pre-miR-30a, and miR-159 KD control oligos. Next, cells were injected in the mammary fat pad of BALB/c mice (5–6 mice per group), and tumor
volume (left panel) and weight (central panel) were registered after 3 weeks. At the end of the 3 weeks, tumors were disaggregated and plated
in a mammosphere formation assay. Number of mammospheres was counted in triplicates for each condition (right panel). P value under 0.05 is
represented with an asterisk (*). B. growth curve for the experiment described in (A). Quantification of tumor volume was performed from day 14
(when tumors are detectable) to day 21. C. An independent experiment was performed in a similar way to (A), using miR-30 family KD oligos
instead of single miR-30a KD P value under 0.05 (two-tailed student t test) is represented with a (*).
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sion of AVEN produced a significant increase in sphere
formation, compared to empty pcDNA3.1 vector (Figure 6C).
These results suggest that AVEN likely has a specific role
in survival under non-attachment conditions in breast
cancer cells. In addition, we assessed the ability of AVEN
to rescue the negative effect of pre-miR30a transfection
(miR-30a overexpression) in the sphere formation assay.
Importantly, we observed lower expression of AVEN when
overexpressing miR30a (pre-miR30a) in both conditions,
empty vector and full length AVEN transfected cells. This
is probably the result of miR30a targeting the endogenous
AVEN, which is expressed at detectable levels under basal
conditions (Figure 6B). Next, we validated the effect of
miR30a overexpression in the presence of an empty
pcDNA3.1 vector under non-attachment conditions
(Figure 6C). miR30a overexpression drastically impairs the
ability to form spheres. As described above, we observed a
significant increase in the number of spheres after trans-
fection with full length AVEN plasmid. Interestingly, full
length AVEN was able to significantly increase sphere for-
mation in the presence of miR30a overexpression to levels
close to control empty-vector levels (Figure 6C).
The negative effect of AVEN silencing in sphere forma-
tion suggests an independent role of this protein in sur-
vival under non-attachment conditions. Moreover, the
ability of AVEN to rescue miR30a effect suggests that
the role of miR30a expression in non-attachment growth
can be partially mediated through targeting of the tran-
script for this anti-apoptotic protein.
Discussion
Due to their ability to simultaneously target multiple tran-
scripts, miRNAs are able to participate in most cellular
processes. In the same way, their deregulation has been
frequently observed in complex human diseases, including
cancer. In this report we studied the potential role of
miRNAs in sustaining the subpopulation of breast cancer
cells with the highest tumor-initiating ability. We identi-
fied miR-30 as a family of miRNAs strongly regulated
under non-attachment conditions of cell growth, a stand-
ard method for selecting BT-ICs. By modulating the ex-
pression of miR-30 family we were able to regulate the
growth in non-attachment conditions, as shown by sphere
formation assays performed in vitro, and ex vivo. Inaddition, upregulation of miR-30 family expression im-
paired tumor growth in a mouse xenograft model. We were
able to further identify potential common targets of miR-30
family with a role in survival and proliferation. These find-
ings explain why a common downregulation of multiple
members of the same miRNA family may be necessary for
sustaining the growth in non-attachment conditions.
An important consideration is the absolute copy number
of miRNAs necessary to target a specific mRNA. This has
been recently addressed using high throughput assays
(Sensor-seq) [25,26]. Interestingly, only a fraction of
detected miRNAs (41%) displayed suppressive activity, and
this activity correlated with a miRNA expression above 100
reads per million, or 100 copies per cell. Our absolute
quantification of miR30a shows approximately 20 copies
per MCF7 cell. Although this is significantly higher than
the number of copies observed in mammospheres, the ab-
solute copy number lies below those reported as biologic-
ally relevant [25,26]. This borderline number of copies may
explain a relatively “mild” effect of miR30a knockdown.
However, based on our own data, many miR30a targets
were common targets to other members of the miR30 fam-
ily. Therefore, the cumulative concentration of miR30 fam-
ily may reach a level beyond biological suppressive activity.
However, we were not able to see an increased effect on
mammosphere formation after silencing the whole miR30
family (data not shown). Other considerations include the
ratio between miRNA and target mRNA abundance, and
the longer half life of miRNAs compared to mRNAs.
We performed the first comprehensive analyses of miR-
30 family targets. Importantly, two recent studies com-
bined proteomics and microarrays to reveal that changes
in protein expression mediated by a miRNA are usually
associated with altered mRNA expression, suggesting that
mRNA degradation may be the major component of
mammalian miRNA repression [4,5]. These recent find-
ings give strong support to our strategy for target identifi-
cation by using mRNA screening.
The importance of different miR-30 family members has
been highlighted in several contexts. miR-30e was shown
to regulate self-renewal and inhibit apoptosis in BT-ICs
[27]. Overexpression of miR-30e in these cells inhibits
their self-renewal capacity by reducing Ubc9, and induces
apoptosis through silencing ITGB3. Although Ubc9 and
ITGB3 were not included in our final list of miR-30a
Figure 6 Role of AVEN in non-attachment growth. A. Sphere
formation assays were performed 48 hours after transfection of
MCF7 cells with esiRNA targeting AVEN. Sphere counting was
performed as in Figure 2. B. MCF7 cells were transfected with empty
pcDNA3.1 vector or a plasmid coding for full length AVEN, in
combination or not with pre-miR30a oligos. Western blots were
performed for the different conditions to test for efficiency of
overexpression. Beta-tubulin was used as housekeeping control. C.
The same conditions used in (B) were tested in a new sphere
formation assay under non-attachment conditions. P values under
0.05 (two-tailed student t test) are represented with an asterisk (*).
The sphere formation plots show the average and standard
deviation of 8 independent non-attachment wells.
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tially involved in apoptosis and proliferation. FOXD1
(forkhead box protein 1) has a role in tumor formation
[28], while AVEN (apoptosis, caspase activation inhibitor)
has an established role in apoptosis regulation [21,24].
Although AVEN is unlikely to be the only miR-30a target
involved in non-attachment growth, our results suggest an
important role in this process that should be followed in
further studies. For example, it would be interesting to
understand the mechanisms by which AVEN rescues
cell death, and whether they differ from the truncated
deltaN-AVEN form [24]. In addition, because of the tran-
sient transfections used in our experiments, our results
may be an underestimation of the role of miR30 and
AVEN, and studies on stable/inducible systems may pro-
vide more drastic effects. In line with our findings, ectopic
expression of miR-30 in BT-ICs xenografts reduced
tumorigenesis and lung metastasis in non obese diabetic/
severe combined immunodeficient mice, whereas blocking
miR-30e expression enhanced tumorigenesis and metasta-
sis [27]. In this sense, miR-30 downregulation may correl-
ate with an in vitro expansion of putative BT-ICs. In
addition, recent studies suggested a role of miR-30 family
in epithelial-mesenchymal transition [29,30] and replica-
tive senescence [31], processes closely linked to stem cell
biology and tumor suppression, respectively.
A potential link between miR-30 expression and clinical
parameters has also been shown. miR-30 was recently
found to be part of a metastatic signature in a series of
breast, bladder, colon and lung cancers [32]. Indeed miR-
30c expression has been suggested as a predictor of endo-
crine therapy in ER+ breast cancer [33]. Interestingly, it was
shown that mir-30 family members are all down-regulated
in both estrogen receptor– and progesterone receptor–
negative tumors, suggesting that expression of these
miRNAs is regulated by these hormones [34]. Indeed, two
members of the miR30 family have been recently shown
to be downregulated by progestins [35]. In addition, miR-
30a-5p, as well as miR-26a and miR-26b, were shown to be
downregulated in tumors with high proliferation index [34].
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Our study indicates that putative BT-ICs enriched in a
mammosphere assay have a distinct miRNA profile, essen-
tial for their proliferation balance. In vitro, this distinct
profile is necessary to acquire the capacity to grow in non-
attachment conditions. In vivo, this profile may be in-
volved in a higher ability to induce tumors. We highlight
the specific role of miR-30 family in these two contexts,




The animal studies have been approved by the Animal
Care Committee of University of Ottawa. All mice re-
ceived normal diet and were monitored daily by the Ani-
mal Care and Veterinary Service-(ACVS) staff. Mice did
not receive any invasive treatment except one time sub-
cutaneous (s.c.) injection of 4T1 cancer cells. The experi-
mental endpoint was a total sacrifice 3 weeks after cancer
cells inoculation. It was chosen to prevent physiological
changes (walking and moving) of mice due to tumor size
and to avoid tumor necrosis. Method of euthanasia: Mice
received injectable Ketamine/Xylazine before cervical dis-
location (0.1 ml of a mix of Ketamine [200 mg/kg] and
Xylazine [100 mg/kg] via IP). The standards for animal
care and use conform with or exceed those defined in the
Canadian Council on Animal Care’s Guide to the Care
and Use of Experimental Animals, Vol. 1, 2nd edn., 1993
and the Animals for Research Act, R.S.O. 1990, c. A.22, s.
17. Study protocol number ME-259.
Cell culture and mammosphere production
Breast cancer cell lines (American Type Culture Collec-
tion) were grown in standard (10% fetal calf serum, 1%
penicillin/streptomycin, 1% sodium pyruvate and 1% glu-
tamine) medium. Slightly attached cells from semi-
confluent culture dishes were centrifuged and plated in
mammosphere conditions, as previously described [36].
Alternatively, cells were counted and tested for viability
with Trypan blue after trypsinization, and plated under
non-attachment conditions with mammosphere medium.
Transfections and luciferase assays
Pre-miR mature microRNA (Pre-miR-30a) sequence (Ap-
plied Biosystems) and knock-down (miR-30a-KD) locked
nucleic acid (LNA) (Exiqon) were used for overexpression
and inhibition of miR-30a, respectively. miR-159 LNA was
used as negative control. Inhibition of the five members of
the miR-30 family (a,b,c,d,e) was obtained using the equi-
molar mix of two oligos, oligo 1 targeting the miR-30a,
miR-30d and miR-30e, and oligo 2 targeting miR-30b and
miR-30c (Exiqon, custom miRNA family knock-down
design).For luciferase assays, MCF7 cells plated in 24-well plates
were transfected with 0.8 μg of the empty pGL3-Basic,
pGL3-Control, pGL3-FOXD1-30UTR, or pGL3-FOXD1
/mut-30UTR. Assays were performed 48h after transfection
using the Dual Luciferasse Reporter Assay system
(Promega), and normalized with Renilla luciferase activity.
All transfections were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Plasmid for AVEN expression assays (full length and
control) ligated into a pcDNA3.1 vector, were a kind gift
from I. Melzer (Frankfurt, Germany), and have been previ-
ously described [24]. For silencing of AVEN we used com-
mercially available endoribonuclease-prepared siRNA
pools (esiRNA) targeting AVEN coding sequence (Sigma).
Transcriptome and MicroRNA expression arrays
Total RNA was extracted using TRIzol (Sigma) according
to the manufacturer’s instructions. For miRNA expression,
RNA labeling and hybridization on Ohio State University
miRNA microarray chips (OSU CCC rel. 4.0) were done
as described elsewhere [37]. For transcriptome analyses,
total RNA from cells transfected with Pre-miR-30, KD-
miR-30a, KD-miR-30 family or control KD-miR-159 was
reverse-transcribed (Ambion Illumina Total Prep) and hy-
bridized on HT12 Human bead chips (Illumina). Valid-
ation of miRNA microarray was performed on Illumina
Human v2 microarray, containing 1146 miRNA probes
(covering 95% of miRBase1 v12.0 known human
miRNAs). Both, miRNA and mRNA expression were also
validated using TaqMan (Applied Biosystems) and SyBR
green (Eurogentec) quantitative RT-PCR, respectively.
Microarray raw data has been deposited in the Gene Ex-
pression Omnibus repository under the accession number
GSE36565 (submitter: Hernandez-Vargas H).
Mouse model experiments
4T1 cells were cultured in RPMI-1640 media (ATCC)
containing 10% FBS, penicillin/streptomycin (0.05 mg/
mL) at 37°C in a humidified atmosphere with 5% CO2.
Six- to 8-week-old BALB/c female mice weighting 18–
20 g (Charles River, Montreal, QC) were randomly distrib-
uted into experimental groups: control, miRNA-30a-KD,
miRNA-159-KD, miRNA-30-family KD, and pre-miR-30a
(5–6 mice per group). Mice were housed in a controlled
atmosphere (temperature 22 ± 2°C; humidity 55 ± 2%)
with a 12 h light/dark cycle. Mice were injected s.c. with
transfected 4T1 cells (1400 cells/0.1 ml/ mice) into the
second left mammary gland fat pad. After three weeks, tu-
mors were collected and weighted. Approximately 0.05 g
of each tumor was minced and dissociated in RPMI-1640
media containing 300 U/ml collagenase (Sigma), and 100
U/ml hyaluronidase (Sigma) at 37°C for 2 h. Cells were
sieved sequentially through a 100 μm and a 40 μm cell
strainer (BD Biosciences) to obtain a single cell
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were plated in ultralow attachment 96-well plates (Costar)
at 104 cells/0.2 ml/well in DMEM-F12 (#12660,
Invitrogen), supplemented with 10 ng/ml EGF, 20 ng/ml
bFGF, 5 μg/ml insulin, 1 mM sodium pyruvate, 0.5 μg/ml
hydrocortisone, and penicillin/streptomycin (0.05 mg/mL).
Cells grown in these conditions as nonadherent spherical
clusters of cells (mammospheres) were counted after
7 days.
4T1 cells were also used to study metastatic behavior.
Because 4T1cells are resistant to 6-thioguanine, micro-
metastatic cells (as few as 1) can be detected in many dis-
tant site organs with better accuracy that most tumour
models. Lungs obtained after the different conditions were
minced and dissociated in RPMI-1640 media containing
300 U/ml collagenase (#C7657, Sigma), at 4°C for 75 min.
After the filtration through a 40 μm cell strainer (BD Bio-
sciences), cells were collected and resuspended in RPMI-
1640 containing 10% FBS (ATCC), penicillin/streptomycin
(0.05 mg/mL) and 60 μM 6-thioguanine 60 (Sigma). Cells
were plated in 10-cm culture dishes (Corning) at 37°C in a
humidified atmosphere with 5% CO2. After 14 days, cells
were fixed by methanol and stained with 0.03% methylene
blue solution. All blue colonies were counted, one colony
representing one clonogenic metastatic cell.Statistical analyses
BRBArrayTools v3.8.1 was used for bead array analysis, as
described above. For other comparisons, means and differ-
ences of the means with 95% confidence intervals were
obtained using GraphPad Prism (GraphPad Software Inc.).
Two-tailed student t test was used for unpaired analysis
comparing average expression between classes. Pearson’s
correlation was used to study the association between
mammosphere formation and metastatic behavior. P
values < 0.05 were considered statistically significant.
Raw miRNA and transcriptome data were background
subtracted, quantile normalized, and further analyzed by
BRB-Array Tools Version 3.8.1 (developed by Dr. Richard
Simon and the BRB-ArrayTools Development Team). For
quantile normalization we used the median array as the
reference array. The normalization is performed by com-
puting a gene-by-gene difference between each array and
the reference array, and subtracting the median difference
from the log-intensities on that array, so that the gene-by
-gene difference between the normalized array and the ref-
erence array is 0.
Gene ontology analyses were performed with the Data-
base for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 using the whole human genome as reference.
In addition, geneset enrichment was done in BRB-Array
Tools for Gene Ontology categories, and biological path-
ways (BioCarta and KEGG).For class comparison analyses p value < 0.001 and false
discovery rate (FDR) < 0.15 were used as cut-offs. Genes
significantly distinguishing the classes were further ana-
lyzed with the miRecords resource (http://mirecords.
biolead.org/prediction_query.php) to identify predicted
targets for miR-30. Only genes predicted by at least 6 out
of 10 miRNA predicting tools were taken into account.
PITA algorithm (http://genie.weizmann.ac.il/pubs/mir07/
mir07_dyn_data.html) was used to identify the seed se-
quences for each gene.Additional files
Additional file 1: Figure S1. miRNA profiling in MCF7 cells, MCF7-
derived mammospheres (MMO), and differentiated mammospheres (DIFF
MMO). miRNA profiling was performed using an oligonucleotide array. A.
Unsupervised cluster analysis and heat-map including all probes. Clustering
of all mammosphere samples indicate a defined profile, distinct from MCF7
and DIFF MMO. B. Volcano plots of fold change (represented in Log2 ratio
in the x axis) vs. P value (represented in Log10 ratio in the y axis). Volcano
plots indicate a subset of miRNAs downregulated in MMO, respective to
MCF7 and DIFF MMO. For comparison, MCF7 and DIFF MMO (in the lower
panel) display a very similar profile.
Additional file 2: Table S1. miRNAs differentially expressed among
MCF7 cells, MCF7-derived mammospheres, and differentiated
mammospheres. Table S2 putative targets of miR-30 after WGE analysis
of miR-30 family KD and Pre-miR-30a.
Additional file 3: Figure S2. Validation of miRNA expression using
Illumina platform. miRNA profiling was validated using Illumina bead
arrays in independent biological replicates of MMO and parental MCF7
cells. A. Scatter plot between 2 technical replicates indicating a proper
correlation. B. Unsupervised cluster analysis and heat-map including all
probes. C. Volcano plots of fold change (represented in Log2 ratio in the
x axis) vs. P value (represented in Log10 ratio in the y axis). Volcano plots
indicate a subset of miRNAs downregulated in MMO, respective to MCF7
cells. D. Expression of selected miRNAs significantly downregulated in
MMO, relative to parental MCF7 cells.
Additional file 4: Figure S3. Absolute quantification of miR-30a copy
number. A. Standards of synthetic miR30a oligonucleotide were used at
known nanomolar concentration in a TaqMan qRT-PCR assay.
Amplification plots are shown in the left panel, and standard curve is
shown in the right panel, with corresponding efficiency and correlation
values. Biological samples were run simultaneously with known miR30a
standards in TaqMan qRT-PCRs. After accounting for the different
dilutions and original number of cells, absolute number of copies per cell
was obtained for parental MCF7 cells compared to MCF7-derived
mammospheres (B), and MCF7 cells treated with different experimental
conditions (MCF7 controls, miR30a overexpression and knock-down) (C).
P values under 0.05 (two-tailed student t test) are represented with an
asterisk (*).
Additional file 5: Figure S4. Whole genome expression after
modulation of miR-30a expression. MCF7 cells were transiently
transfected with different conditions, miR-30a-k.d., Pre-miR-30a, and
control miR-159-k.d. After 48 hours, RNA was extracted from biological
triplicates, and interrogated for whole genome expression with Illumina
HT12 bead arrays. A. Scatter plot between 2 technical replicates
indicating a proper correlation. B. Cluster analysis and heat-map
including all probes differentially expressed between Pre-miR-30a and
miR-159 control k.d. As can be seen, no transcripts were significantly
different between miR-30a-k.d. and miR-159 control k.d. C. Expression of
selected miRNAs was validated by qRT-PCR in independent biological
triplicates. Downregulation was as expected in cells overexpressing miR-
30a (Pre-miR-30a), while no differences were found after miR-30a k.d,
confirming the results from the whole genome expression assay. P values
under 0.05 (two-tailed student t test) are represented with an asterisk (*).
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http://www.biomedcentral.com/1471-2164/14/139Additional file 6: Table of Gene Sets: 420 gene sets sorted by LS
permutation p-value (significant p-values are in red). Table of Gene
Sets: 42 gene sets sorted by LS permutation p-value (significant p-values
are in red). Table of Gene Sets: 43 gene sets sorted by LS permutation p-
value (significant p-values are in red).
Additional file 7: Figure S5. Lung metastasis assay after modulation of
miR30 expression. 4T1 mammary cancer cells were transiently transfected
with miR-30a family KD, Pre-miR-30a, and miR-159 KD control oligos.
Next, cells were injected in the mammary fat pad of BALB/c mice and
tumor growth was followed during 21 days (experiment shown in
Figure 5C). Lungs obtained after the different conditions were minced,
dissociated, and cells were suspended in medium containing 6-
thioguanine and plated in culture dishes. After 14 days, cells were fixed
by methanol and stained with methylene blue solution (A). All blue
colonies were counted, one colony representing one clonogenic
metastatic cell (B).
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